Ironwood Pharmaceuticals (IRWD) Other Non-Current Liabilities (2011 - 2026)

Ironwood Pharmaceuticals (IRWD) has 15 years of Other Non-Current Liabilities data on file, last reported at $21.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 22.43% year-over-year to $21.2 million; the trailing twelve-month figure through Mar 2026 stood at $21.2 million (up 22.43% YoY), and the FY2025 full-year result was $21.6 million, up 26.56% from the prior year.
• Other Non-Current Liabilities slipped to $21.2 million in Q1 2026, from $21.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $39.8 million in Q3 2024 to a low of $5.1 million in Q1 2022.
• A 5-year average of $21.1 million and a median of $21.6 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities jumped 478.86% in 2022 and tumbled 44.14% in 2025, its largest moves.
• Tracing IRWD's Other Non-Current Liabilities over 5 years: stood at $9.8 million in 2022, then soared by 190.96% to $28.4 million in 2023, then slumped by 39.8% to $17.1 million in 2024, then grew by 26.56% to $21.6 million in 2025, then retreated by 2.21% to $21.2 million in 2026.
• Business Quant data shows IRWD's Other Non-Current Liabilities at $21.2 million in Q1 2026, $21.6 million in Q4 2025, and $22.2 million in Q3 2025.